Galvus
(Vildagliptin)Phase 3Small molecule
NovartisVildagliptin is used to treat type 2 diabetes by helping the pancreas produce more insulin when blood sugar levels are high, and it works by preventing the breakdown of hormones that regulate blood sugar.[1] Galvus is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]
Galvus is one of 150 small molecule programs targeting Cognition. It is currently in Phase 3.
4
Indications
152
Total Trials
6
Active Trials
149
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
228 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Savaysa
Daiichi SankyoPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Rilutek
AAzurity Pharmaceuticals
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 3
Galvus
NovartisPhase 3
Becotatug Vedotin
FFudan University
Phase 3
Apatinib Mesylate
BBukwang Pharmaceutical
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes71 trials
Show 68 more trials
Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension
Completed·—·Phase 4·NCT02145611·50 enrolled
Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes
Completed·—·Phase 4·NCT04916093·60 enrolled
Type 2 Diabetes Mellitus11 trials
Show 8 more trials
Metformin6 trials
Show 3 more trials
Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin
Completed·CCentre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète·Phase 4·NCT01757587·39 enrolled
Type 2 Diabetic Patients4 trials
Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients
Completed·—·N/A·NCT06068686·70 enrolled
Renal insufficiency4 trials
47 more indications
Lip3 trials
Type 1 Diabetes2 trials
Function2 trials
Insulin Secretion2 trials
Efficacy and Safety2 trials
ESS2 trials
GLP-11 trial
Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion
Completed·—·Phase 1·NCT02749032·24 enrolled
Patient Preference1 trial
Efficacy1 trial
Type 1 Diabetes Mellitus1 trial
Cognition1 trial
Diabetes, Type 21 trial
Gestational Diabetes1 trial
ART1 trial
Cardiovascular1 trial
Prevention1 trial
Drug1 trial
Cognitive Protective Effect of Newer Antidiabetic Drugs
Unknown status·—··NCT05347459·100 enrolled
Treatment1 trial
Safety and Efficacy1 trial
Diabetes Mellitus1 trial
Metabolic Syndrome1 trial
Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression
Unknown status·—·Phase 4·NCT04485845·39 enrolled
Neuropathy1 trial
Inflammation1 trial
Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD
Completed·—·Phase 4·NCT03693560·80 enrolled
Major Depressive Disorder1 trial
Empagliflozin1 trial
Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
Completed·—·N/A·NCT06313008·120 enrolled
Congestive Heart Failure1 trial
Impaired glucose tolerance1 trial
PreDiabetes1 trial
Cystic1 trial
Diabetes Mellitus, Type 21 trial
Open-label, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes.
Completed·FFundación para la Investigación del Hospital Clínico de Valencia·Approved·NCT06851962·92 enrolled
Unspecified3 trials
Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor
Completed·—·Phase 4·NCT03178591·43 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vildagliptin. EMBL-EBI & Wellcome Sanger Institute.
- [4]